Full Title
A Randomised Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Previously Untreated Stage IA/IIA Hodgkin LymphomaPurpose
Researchers in this study are comparing two different treatments for Hodgkin lymphoma (HL). The people in this study have early-stage (stage 1 or 2) HL that has not yet been treated.
A standard initial treatment for people with early-stage HL includes the chemotherapy drugs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Researchers think that replacing bleomycin with brentuximab vedotin (A2VD) may be more effective. HL has high levels of a protein called CD30, which can cause cancer cells to grow. Brentuximab vedotin targets and kills cancer cells with CD30. By targeting these cells, brentuximab vedotin may help slow or stop the growth of your cancer.
A2VD is used to treat advanced HL; its use to treat early-stage HL is considered investigational. If you join this study, you will be randomly assigned to get one of these treatments:
- Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
- Doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine (A2VD)
Doxorubicin is given as an injection and the other drugs are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have stage 1 or 2 Hodgkin lymphoma that has not yet been treated.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 16-69.
Contact
For more information or to see if you can join this study, please call Dr. Allison Moskowitz’s office at 646-608-3726.